Market News & Trends
CERo Therapeutics Successfully Completes IND-Enabling Toxicology Studies for Lead Compound
CERo Therapeutics Holdings, Inc. recently announced the successful completion of toxicology studies for its lead compound, CER-1236. The toxicology studies will be included in the…
ArriVent Announces Multi-Target ADC Collaboration With Alphamab
ArriVent BioPharma, Inc. recently announced it has entered into a collaboration agreement with Jiangsu Alphamab Biopharmaceuticals Co., Ltd. to discover, develop and commercialize novel antibody…
Ocean Biomedical Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results
Ocean Biomedical, Inc. congratulated its JV partner Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, on its late breaker presentation highlighting the…
Nucleus RadioPharma Secures Series A Extension Funding With AstraZeneca Investment
Nucleus RadioPharma recently announced the closing of a Series A extension round with new investor AstraZeneca. AstraZeneca joins existing investors from GE Healthcare, Mayo Clinic,…
Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor
Assembly Biosciences, Inc. recently announced new data for ABI-6250, the company’s orally bioavailable, small molecule hepatitis D virus (HDV) entry inhibitor candidate, featured in a…
Gerresheimer to Acquire Blitz LuxCo Sarl, the Holding Company of the Bormioli Pharma Group
Gerresheimer underpins leading market position as a full-service provider for the pharmaceutical and biotech industries….
SCHOTT Pharma & KORU Medical Systems Collaborate to Advance Large-Volume Subcutaneous Infusion
SCHOTT Pharma and KORU Medical Systems are joining forces to offer a high volume subcutaneous drug infusion solution…..
First Participants Vaccinated in IMUNON’s Phase 1 Clinical Trial
IMUNON, Inc. recently announced the first participants have been treated in the IMNN-101 Phase 1 clinical trial. This proof-of-concept study of IMUNON’s proprietary PlaCCine platform…
Osteal Therapeutics Closes $5-M Financing to Support Approval & Commercial Launch of Lead Candidate
Osteal Therapeutics, Inc. recently announced the completion of an oversubscribed $50-million Series D preferred stock equity financing. Zimmer Biomet led the round, joined by returning…
Proton Therapy Demonstrates Advantages in Phase 3 Head & Neck Cancer Trial
According to preliminary data from a multi-institution Phase 3 trial led by researchers at The University of Texas MD Anderson Cancer Center, intensity modulated proton…
Wistar Scientists Develop Novel Antibody Treatment for Kidney Cancer
Advanced clear cell renal cell carcinoma (ccRCC) is a deadly form of kidney cancer with few treatment options; even with new immunotherapies, only around one…
ExeVir Bio Announces Exceptional Virus Neutralization Potency of its Variant-Proof Antibody Against the SARS-CoV-2 Variant JN.1
ExeVir Bio recently announced new data demonstrating its antibodies are exceptionally potent in neutralizing the SARS-CoV-2 variant JN.1, the parental strain of the currently most…
Kindeva Drug Delivery Expands Facilities to Support Growth of Green Propellant Commercialization
Kindeva Drug Delivery recently announced the expansion of their Loughborough, UK, facilities at the Charnwood Campus Science Innovation and Technology Park. This strategic move by…
Biolojic Design Enters Multi-Target Drug Discovery Collaboration With Merck KGaA
Merck KGaA, Darmstadt, Germany, will leverage Biolojic Design’s AI capabilities to create potential best-in-class multi-specific antibodies that uniquely modulate biology….
Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients With Tenosynovial Giant Cell Tumor
Deciphera Pharmaceuticals, Inc. recently announced that results from the company’s MOTION pivotal Phase 3 study of vimseltinib in patients with TGCT are being highlighted in…
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies
Denali Therapeutics Inc. recently announced the US FDA has selected DNL126 for participation in the Support for clinical Trials Advancing Rare disease Therapeutics (START) Pilot…
Ecolab Life Sciences & Repligen Announce Commercial Launch of DurA Cycle Affinity Resin for Large-Scale Biologic Manufacturing
St. Paul, MN, US and Waltham, MA, US – June 3, 2024 – Ecolab today announced that its Purolite resin business, together with Repligen Corporation (NASDAQ:RGEN), a life…
Longeveron Announces Contract Development & Manufacturing Business & First Contract
Longeveron Inc. recently announced the launch of its contract development and manufacturing business at the company’s 15,000-sq-ft state-of-the-art Good Manufacturing Practice (GMP) facility. This facility contains….
Aeterna Zentaris & Ceapro Complete Merger Transaction
Aeterna Zentaris Inc. and Ceapro Inc. recently announce the successful completion and closing of their all-stock merger of equals transaction (the Transaction), which was previously announced by….
uniQure Receives FDA Regenerative Medicine Advanced Therapy Designation for Investigational Gene Therapy in Huntington’s Disease
uniQure N.V. recently announced the US FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation for its investigational gene therapy AMT-130 for the treatment of…
